Sanyou Biopharmaceuticals

Sanyou Biopharmaceuticals Co., Ltd. is a pioneering company in the field of biological drug research and development, offering comprehensive solutions for drug R&D, development, and manufacturing. The company's 4C business model, comprising differentiated CRO, integrated CDO, innovative CPO, and characteristic CRS, aims to simplify R&D processes for innovative biologics. Sanyou Biopharmaceuticals is committed to maintaining the highest quality standards, evident through its ISO 9001 quality assurance and GB/T intellectual property management certifications, ensuring the protection of its clients' interests. Founded in 2015 and headquartered in the United States, the company recently secured a Series B investment on 02 August 2022 from a group of prominent investors including LH Ventures, Huatai Zijin Investment, Shenzhen Qianhai Beizeng Asset Management, and Guohai Xia. With its strong focus on innovation and quality, Sanyou Biopharmaceuticals is well-positioned to make significant strides in the biotechnology and pharmaceutical industries. Learn more at www.sanyoubio.com and crs.sanyoubio.com.